Skip to main content
    O

    OUTLOOK THERAPEUTICS INC (OTLK)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.40
    -0.02 (-4.12%)

    Market Cap: $100.54M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    OUTLOOK THERAPEUTICS INC (OTLK) Earnings: Report Dates and Results

    Updated Aug 13, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    OUTLOOK THERAPEUTICS INC (OTLK) is expected to report earnings on Dec 17, 2026. In the quarter ended Jun 30, 2026, OUTLOOK THERAPEUTICS INC reported EPS of -$0.09, in line with the -$0.09 estimate. It beat the EPS estimate in 2 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    38%(15/39)
    Avg Surprise
    -7.29%

    Upcoming Estimates

    Reports Dec 17, 2026 (est.)Period ending Sep 30, 2026
    EPS Consensus-$0.06
    Range-$0.08 - -$0.02
    6 analysts
    Revenue Consensus
    $3.31M
    Range$1.47M - $5.70M
    6 analysts
    Reports Feb 15, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.05
    Range-$0.08 - -$0.01
    3 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.08+37.7%
    60d ago-$0.08+37.7%
    30d ago-$0.05+6.6%
    7d ago-$0.05+6.6%
    Current-$0.05
    Revenue Consensus
    $5.30M
    Range$1.30M - $8.90M
    4 analysts

    Next Report

    OTLK has an expected report date of Dec 17, 2026.

    OTLK Earnings Call

    The latest OTLK earnings call transcript on file is labeled 2024Q3.

    Read the 2024Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, OTLK beat 15, missed 22 and matched 3. Revenue for the quarter ended Jun 30, 2026 was $9000, down 99.4% from $1.51M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Jun 30, 2026-$0.09-$0.09-$0.10 - -$0.050.00%In lineN/A21 up, 0 downAug 13, 2026$9000
    Mar 31, 2026-$0.17-$0.12-$0.15 - -$0.07-41.67%MissN/A31 up, 1 downMay 15, 2026$127439
    Dec 31, 2025-$0.22-$0.17-$0.27 - -$0.09-29.41%Miss-130.6%31 up, 0 downFeb 17, 2026N/A
    Sep 30, 2025-$0.28-$0.06N/A-366.67%MissN/A41 up, 0 downDec 19, 2025N/A
    Jun 30, 2025-$0.44-$0.39-$0.45 - -$0.33-12.82%MissN/A21 up, 0 downAug 14, 2025$1.51M
    Mar 31, 2025-$0.40-$0.55-$0.61 - -$0.45+27.27%BeatN/A31 up, 1 downMay 15, 2025N/A
    Dec 31, 2024$0.72-$0.62N/A+216.13%BeatN/A10 up, 0 downFeb 14, 2025$170124
    Sep 30, 2024-$0.94-$0.90-$0.91 - -$0.89-4.10%MissN/A21 up, 1 downDec 27, 2024$170124
    Jun 30, 2024-$0.83-$0.84-$1.43 - -$0.75+1.19%BeatN/A40 up, 0 downAug 14, 2024N/A
    Mar 31, 2024-$1.55-$1.07-$1.20 - -$0.43-44.86%MissN/A60 up, 0 downMay 15, 2024N/A
    Dec 31, 2023-$0.78-$1.07-$1.20 - -$0.80+27.10%BeatN/A61 up, 0 downFeb 14, 2024N/A
    Sep 30, 2023-$0.05-$0.06-$0.07 - -$0.05+16.67%BeatN/A81 up, 0 downDec 22, 2023N/A
    Jun 30, 2023-$1.38-$0.87-$1.60 - -$0.60-58.62%MissN/A70 up, 0 downAug 14, 2023N/A
    Mar 31, 2023-$0.52-$1.20-$1.80 - -$1.00+56.67%BeatN/A60 up, 0 downMay 15, 2023N/A
    Dec 31, 2022-$1.59-$1.30-$1.80 - -$0.20-22.31%MissN/A40 up, 0 downFeb 14, 2023N/A
    Sep 30, 2022-$0.06-$0.07-$0.08 - -$0.05+14.29%BeatN/A41 up, 0 downDec 29, 2022N/A
    Jun 30, 2022-$1.56-$1.33N/A-17.29%MissN/AN/A0 up, 0 downAug 10, 2022N/A
    Mar 31, 2022-$1.77-$1.20-$1.40 - -$1.20-47.50%MissN/A30 up, 0 downMay 13, 2022N/A
    Dec 31, 2021-$0.08-$0.06-$0.07 - -$0.05-33.33%MissN/A20 up, 0 downFeb 14, 2022N/A
    Sep 30, 2021-$1.60-$1.27-$1.40 - -$1.00-25.98%MissN/A20 up, 0 downDec 22, 2021N/A
    Jun 30, 2021-$1.40-$1.40-$1.60 - -$1.200.00%In lineN/A3N/AAug 13, 2021N/A
    Mar 31, 2021-$1.80-$1.80-$1.80 - -$1.400.00%In lineN/A2N/AMay 14, 2021N/A
    Dec 31, 2020-$2.20-$1.65-$1.80 - -$1.40-33.33%MissN/A2N/AFeb 16, 2021N/A
    Sep 30, 2020-$0.13-$0.08-$0.09 - -$0.07-62.50%MissN/A2N/ADec 23, 2020N/A
    Jun 30, 2020-$2.20-$1.90-$3.20 - -$1.20-15.79%MissN/A2N/AAug 14, 2020N/A
    Mar 31, 2020-$2.60-$2.45-$4.20 - -$2.00-6.12%MissN/A2N/AMay 15, 2020N/A
    Dec 31, 2019-$5.60-$4.40-$5.60 - -$3.80-27.27%MissN/A3N/AFeb 14, 2020$5.85M
    Sep 30, 2019-$0.12-$0.31-$0.32 - -$0.28+61.29%BeatN/A3N/ADec 19, 2019$5.85M
    Jun 30, 2019-$4.80-$7.27-$8.40 - -$5.40+33.98%BeatN/A3N/AAug 14, 2019$583848
    Mar 31, 2019-$19.26-$13.20N/A-45.91%MissN/AN/AN/AMay 15, 2019$641140
    Dec 31, 2018-$14.40-$49.60N/A+70.97%BeatN/AN/AN/AFeb 14, 2019$1.07M
    Sep 30, 2018-$0.32-$0.23N/A-39.13%MissN/AN/AN/ADec 18, 2018$771890
    Jun 30, 2018-$32.00-$36.80N/A+13.04%BeatN/AN/AN/AAug 14, 2018$771890
    Mar 31, 2018-$51.20-$36.80N/A-39.13%MissN/AN/AN/AMay 15, 2018$771890
    Dec 31, 2017-$2.48-$1.92N/A-29.17%MissN/AN/AN/AFeb 14, 2018$771890
    Sep 30, 2017-$35.76-$99.20N/A+63.95%BeatN/AN/AN/ADec 29, 2017$2.90M
    Jun 30, 2017-$59.42-$102.40N/A+41.97%BeatN/AN/AN/AAug 14, 2017$303140
    Mar 31, 2017-$61.25-$152.00N/A+59.70%BeatN/AN/AN/AJun 28, 2017$303140
    Dec 31, 2016-$131.20-$153.60N/A+14.58%BeatN/AN/AN/AFeb 14, 2017$303140
    Sep 30, 2016-$4.96-$4.48N/A-10.71%MissN/AN/AN/ADec 29, 2016$494894
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Sep 30, 2026 was -$0.48, after -$0.40 the year before. It was -$287.63 for the year ended Sep 30, 2017, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Sep 30, 2026-$0.48N/A
    Sep 30, 2025-$0.40N/A
    Sep 30, 2024-$4.10N/A
    Sep 30, 2023-$3.54N/A
    Sep 30, 2022-$3.47N/A
    Sep 30, 2021-$7.00N/A
    Sep 30, 2020-$10.53N/A
    Sep 30, 2019-$38.58N/A
    Sep 30, 2018-$86.00N/A
    Sep 30, 2017-$287.63N/A

    Earnings Calls

    The 2 most recent earnings calls are listed below; the latest, 2024Q3 for the period ended Sep 30, 2024, runs about 3,100 words across 9 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2024Q3Sep 30, 20243,0859
    2024Q2Jun 30, 20245,34811

    2024Q3 Earnings Call

    Opening remarks

    Jenene Thomas Investor Relations Thank you, Donna. At this time, I'd like to remind our listeners that remarks made during this webcast may state management's intentions, beliefs, expectations for future projections, including but not limited to our expectations about the timing of clinical trials and commercial launch and the sufficiency of our cash resources. These are forward-looking statements and involve risks and uncertainties. Forward-looking statements on this call are made pursuant to the Safe Harbor provisions of the federal securities laws and are based on Outlook Therapeutics current expectations, and actual results could differ materially. As a result, you should not place undue reliance on any forward-looking statements. Some of the factors that could cause actual results to differ materially from these contemplated by such forward-looking statements are discussed in the periodic report, Outlook Therapeutics files with the Securities and Exchange Commission. These documents are available in the Investors section of the company's website and on the Securities and Exchange Commission's website. We encourage you to review these documents carefully. Additionally, certain information contained in this webcast relates to or is based on studies, publications, surveys, and other data obtained from third-party sources and the company's own estimates and research. While the company believes that these third-party sources to be reliable, as of the date of this presentation that has not been independently verified and makes no representation as to the adequacy, fairness, accuracy, or completeness of that or that any independent source has verified any information from third-party sources. During the call, management will discuss non-GAAP financial measures, which are not prepared in accordance with US generally accepted accounting principles. Definition of these non-GAAP financial measures, along with reconciliations of the most directly comparable GAAP financial measures are included in Outlook Therapeutics third quarter earnings release which has been furnished to the SEC and is available on the company's website at ir.outlooktherapeutics.com. Joining us on the call from Outlook Therapeutics leadership team are Russell Trenary, President and Chief Executive Officer; and Lawrence Kenyon, Chief Financial Officer of Outlook Therapeutics. I’d now like to turn the call over to Russ Trenary. Please proceed.

    Russell Trenary CEO Thank you, Jenene, and thank you to everyone joining us for our third quarter fiscal year 2024 conference call and webcast. As we begin today's call, I think it's important for me to start with our mission, and that is quite simply to achieve the first-ever approval for an ophthalmic formulation of bevacizumab for the treatment of retina diseases, initially in the EU, UK, and US. We're working toward achieving that mission in real time.

    Frequently Asked Questions About OTLK

    When is OUTLOOK THERAPEUTICS INC's next earnings date?

    OUTLOOK THERAPEUTICS INC's next earnings report is expected for Dec 17, 2026.

    Did OTLK beat earnings estimates last quarter?

    OUTLOOK THERAPEUTICS INC reported EPS of -$0.09 for the quarter ended Jun 30, 2026, in line with the -$0.09 estimate.

    What EPS do analysts expect from OTLK next quarter?

    The consensus EPS estimate for OUTLOOK THERAPEUTICS INC for the quarter ended Sep 30, 2026 is -$0.06 from 6 analysts, with estimates from -$0.08 to -$0.02.

    How often does OTLK beat earnings estimates?

    OUTLOOK THERAPEUTICS INC beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -26.41%.